Turn Therapeutics Inc. Common Stock (TTRX)
Stock · NASDAQ · Health Care
$10.57as of 10/16/2026
Price chart
Active signals
Support level
$9.49
Industry
Biotechnology: Pharmaceutical Preparations
About TTRX
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 2
- Website
- turntherapeutics.com
Fundamentals
- 1-day range
- $12.07$13.88
- Market cap
- $286.26M
- P/E (trailing)
- —
- P/E (forward)
- -88.40
- EPS (trailing)
- $-0.29
- Dividend yield
- —
- Beta
- 0.27
- Avg. volume
- 117.1K
52-week range
$2.57$26.5
Next earnings: November 12, 2026 · EPS estimate $-0.02confirmed
Forecasts
2 analyst ratings
Buy 88%
Hold 13%
Sell 0%
1-year price forecast
High
$26
+146.0%
Median
$25
+136.5%
Low
$24
+127.1%
Turn Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TTRXTurn Therapeutics Inc. Common Stock$10.57▼ 8.80%Market cap $286.26MP/E —$2.57$26.5
- FULCFulcrum Therapeutics Inc. Common Stock$3.65▼ 0.54%Market cap $287.64MP/E —$2.83$15.74
- IMRXImmuneering Corporation Class A Common Stock$3.59▼ 1.37%Market cap $288.55MP/E —$3.6$8.48
- ALXOALX Oncology Holdings Inc. Common Stock$1.06▲ 6.00%Market cap $283.93MP/E —$0.8617$2.66
- CAMPCAMP4 Therapeutics Corporation Common Stock$3.17▼ 8.12%Market cap $282.25MP/E —$2.86$7.75
- BCYCBicycle Therapeutics plc American Depositary Shares$3.46▼ 3.89%Market cap $277.87MP/E —$3.33$9.08
- EBSEmergent BioSolutions Inc. Common Stock$6.38▼ 11.14%Market cap $273.98MP/E —$4.36$14.06
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TTRX Turn Therapeutics Inc. Common Stock | $286.26M | — | $10.57 | ▼ 8.80% | $2.57$26.5 |
| FULC Fulcrum Therapeutics Inc. Common Stock | $287.64M | — | $3.65 | ▼ 0.54% | $2.83$15.74 |
| IMRX Immuneering Corporation Class A Common Stock | $288.55M | — | $3.59 | ▼ 1.37% | $3.6$8.48 |
| ALXO ALX Oncology Holdings Inc. Common Stock | $283.93M | — | $1.06 | ▲ 6.00% | $0.8617$2.66 |
| CAMP CAMP4 Therapeutics Corporation Common Stock | $282.25M | — | $3.17 | ▼ 8.12% | $2.86$7.75 |
| BCYC Bicycle Therapeutics plc American Depositary Shares | $277.87M | — | $3.46 | ▼ 3.89% | $3.33$9.08 |
| EBS Emergent BioSolutions Inc. Common Stock | $273.98M | — | $6.38 | ▼ 11.14% | $4.36$14.06 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- WBB Securities Downgrades Turn Therapeutics to Sell, Announces $10 Price TargetBenzinga · 9/14/2026
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · 9/11/2026
Insider Activity
Insider Actions →Acquired
339.6K
Disposed
300.0K
- Martin William Dewhurst · June 4, 2026 · Grant71.7K
- Kent Edward Kester · June 4, 2026 · Grant83.3K
- Andrew Gengos · June 4, 2026 · Grant95.0K
- Arthur F. Golden · June 4, 2026 · Grant89.6K
- BEB Holdings, LLC · May 28, 2026 · Gift300.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 449.8K
- Total value held
- $1.44M
- Institutional holders
- 19
Top holders this quarter
- Unknown70.5K
- Unknown69.8K
- Unknown65.7K
- Unknown49.5K
- Unknown30.0K
- Unknown23.7K
- Unknown19.7K
- Unknown19.7K
- Unknown18.0K
- Unknown17.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Lucid Capital initiates coverage on TTRX with $24 target
Lucid Capital Markets has begun tracking Turn Therapeutics, assigning a Buy rating and setting a price target of $24. This new analyst note adds to the current average target of $25. The stock is currently trading well below its 52-week high, providing context for the new coverage initiation.
Lucid Capital initiates coverage on TTRX with $24 target. Lucid Capital Markets has begun tracking Turn Therapeutics, assigning a Buy rating and setting a price target of $24. This new analyst note adds to the current average target of $25. The stock is currently trading well below its 52-week high, providing context for the new coverage initiation.